MedicaidCoverageMedium impact
Zolgensma® (Onasemnogene Abeparvovec-Xioi)
UnitedHealthcare·NM · Genetics, Neurology, Pediatrics·Medical Benefit Drug Policy
Effective date
Oct 1, 2026
We identified it
Sep 2, 2026
Summary
UnitedHealthcare Community Plan of New Mexico has issued a revised medical benefit drug policy for Zolgensma® (Onasemnogene Abeparvovec-Xioi) effective October 1, 2026. The policy details coverage requirements, limitations, and medical necessity criteria for this gene therapy treatment. Billing teams must review the full policy document to identify any changes to prior authorization requirements, covered indications, or billing procedures compared to previous guidance.
Action Required
By September 30, 2026: Billing team and providers must obtain and review the complete policy text from the source URL. Identify any changes from previous Zolgensma® policy versions regarding: (1) prior authorization requirements and submission processes, (2) covered patient populations and medical necessity criteria, (3) billing codes and reimbursement rates, (4) documentation requirements for claims. Update billing software, encounter templates, and prior auth workflows accordingly. Communicate changes to all providers ordering or administering Zolgensma®. Beginning October 1, 2026, ensure all claims comply with the revised policy requirements to avoid denials.